The Short Story of a 15% DeclineWe find ourselves in a challenging situation. Over the past two years, the stock has been in a sustained upward trend. However, over the past month, we have been testing the current support level extensively, which raises concerns about the stock's resilience at this point. The formation of a double top is particularly noteworthy, as this pattern often signals a potential reversal.
This stock has historically exhibited highly consistent and conservative behavior, closely adhering to technical patterns. As such, I do not anticipate any unexpected deviations. Based on the current analysis, I foresee a 15% probability of a decline within the next month.
A3C4MS trade ideas
Roivant Sciences (ROIV): A Multibagger Stock Opportunity
Roivant Sciences (ROIV) is poised for significant growth with a strong pipeline, including potential blockbusters like Batoclimab and Brepocitinib in the autoimmune space. Recent deals, including the $5.2B sale of Telavant, have strengthened their balance sheet and set the stage for future profitability. Upcoming Q4 catalysts, a $1.5B buyback program, and a solid focus on pulmonary hypertension therapies make ROIV an undervalued gem at its current price.
Personal Note: Hi, I'm sharing insights on stocks with strong catalysts like ROIV. Follow me for more deep dives and stock picks.
Sorry Vivek... this does not look good for you :/Price target 1 - $7
Price target 2 - $5
This has nothing to do with Vivek personally, but this is very clearly setting up for a LARGE move down.
If all is untrue with my analysis and earnings are promising, I can see a pop to $15 per share.
Earnings for a company that has a 7.8 billion dollar market cap, BETTER deliver.
SHORT IT... I'm sorry Vivek, I really like you but stocks don't care about our feelings.
ROIV – 20% Trading RangeNASDAQ:ROIV is trading near all time highs, and I just don’t see any good investment opportunity here. However, I do like that there is a nice trading range between the red and green trendlines with 20% swings. I would definitely trade these swings, it looks like there was a recent opportunity that was missed. But I’ll track ROIV to look for the next setup.
A bit confused...It's really hard to say what's going to be. But I can say, this momentum is very important, and in the next days will form a new direction.
The uncertainty of the situation is big. There is a bullish trend, and the RSI signs the break of the bearish trend. But something's not right, maybe the 12.00 tops, or the temptation of the 8.30 level.
Stay informed, and watch the chart, something very important will happen.
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two
days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines
On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and
volatility show both are heightened in the pre-earnings run- up. The last report in November
was a double beat which is good prognosis for the one upcomings. This is a risky earnings
play, ROIV does not yet make money. However, because it lost less than forecasted, buyer
interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00
per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top
at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%).
Considering that ROIV has gained 12% this past week, 7% in the next two days is about the
same trend angle. As to the call contract, I have considered 100% return as my expections
for the two days before the earnings. If earnings disappoint trader expectations and price fades
I will sell to close the contract. If earnings is as expected, I will roll the contract forward into
the March monthly and add a bit more capital into the trade.